Biocryst Pharmaceuticals reported $622.18M in Debt for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
DBV Technologies DBVT:US 0 0
Alnylam Pharmaceuticals ALNY:US $ 677.72M 1.01M
Biocryst Pharmaceuticals BCRX:US $ 622.18M 17.72M
Chemocentryx CCXI:US $ 23.72M 0.04M
Chugai Pharma 4519:JP Y 0M 0M
Daiichi Sankyo 4568:JP Y 163367M 94M
Enanta Pharmaceuticals ENTA:US $ 1.51M 0M
GlaxoSmithKline GSK:LN 22111M 11217M
Glaxosmithkline GSK:US $ 22111M 11217M
Intra Cellular Therapies ITCI:US $ 0M 0M
IONIS PHARMACEUT IONS:US $ 1253.13M 1M
Karyopharm Therapeutics KPTI:US $ 302.69M 202K
Mirati Therapeutics MRTX:US $ 0M 0M
Neurocrine Biosciences NBIX:US $ 169M 208.7M
Novavax NVAX:US $ 448.43M 7.93M
Ptc Therapeutics PTCT:US $ 1207.54M 10.46M
Regeneron Pharmaceuticals REGN:US $ 2700.7M 0.3M
Sarepta Therapeutics SRPT:US $ 1100.87M 2.03M
Ultragenyx Pharmaceutical RARE:US $ 0M 0M
Vertex Pharmaceuticals VRTX:US $ 482.3M 13.2M
YTE INCY:US $ 34.19M 0.01M